Abeona Therapeutics
ABEO
58 hedge funds and large institutions have $28.3M invested in Abeona Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 17 closing their positions.
167% more call options, than puts
Call options by funds: $139K | Put options by funds: $52K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.93% less ownership
Funds ownership: 27.85% → 24.92% (-2.9%)
17% less funds holding
Funds holding: 70 → 58 (-12)
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
65% less capital inflows, than outflows
Capital inflows: $1.77M | Capital outflows: $5.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$416K |
| 2 |
ACT Capital Management
Wayne,
Pennsylvania
|
+$356K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$327K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$202K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$1.45M |
| 2 |
Millennium Management
New York
|
-$875K |
| 3 |
Morgan Stanley
New York
|
-$617K |
| 4 |
Tibra Equities Europe
London,
United Kingdom
|
-$312K |
| 5 |
JP Morgan Chase
New York
|
-$297K |
ABEO Hedge Fund Activity: Q3 2021 in Review
58 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2021, worth a combined $28.3M — down 35% from $43.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ABEO and 6 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 10 added.
The largest buyer was Franklin Resources, opening a new position worth an estimated $416K. The largest seller was Russell Investments Group, exiting entirely with an estimated $1.45M sold.
- 58 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2021, down from 70 in Q2 2021.
- Funds reported $28.3M of Abeona Therapeutics stock for Q3 2021, down 35% quarter-over-quarter.
- 6 funds opened new Abeona Therapeutics positions in Q3 2021 and 17 closed out, a net change of -11 holders.
- The largest Abeona Therapeutics buyer in Q3 2021 was Franklin Resources, an estimated $416K added.
- The largest Abeona Therapeutics seller in Q3 2021 was Russell Investments Group, an estimated $1.45M sold.
Based on aggregated 13F filings for Q3 2021.